Author:
Greig N. H.,De Micheli E.,Holloway H. W.,Yu Q.-S.,Utsuki T.,Perry T. A.,Ingram D. K.,Deutsch J.,Lahiri D.,Soncrant T. T.
Subject
Clinical Neurology,Neurology,General Medicine
Cited by
66 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease;Alzheimer's Research & Therapy;2024-07-05
2. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer’s Disease;2024-03-22
3. Structural Scaffolds as Anti- Alzheimer Agents;Medicinal Chemistry;2023-02
4. Recent advance on carbamate-based cholinesterase inhibitors as potential multifunctional agents against Alzheimer's disease;European Journal of Medicinal Chemistry;2022-10
5. In Silico and Ex Vivo Analyses of the Inhibitory Action of the Alzheimer Drug Posiphen and Primary Metabolites with Human Acetyl- and Butyrylcholinesterase Enzymes;ACS Pharmacology & Translational Science;2022-01-12